VEGFA and glioblastoma: In addition to nanotherapeutic approaches, we also compared the outcomes to prior data from therapy using Bevacizumab, a monoclonal antibody drug that inhibits the VEGF pathway and has been widely used for adjunct GBM therapy [40,79].